SUCLA2 gene is frequently involved in the deletion of RB1 gene region, which occurs in 10 – 30 % of advanced prostate cancers. SUCLA2 deletion gives rise to a metabolic vulnerability. By screening chemical compounds, thymoquinone appeared to selectively kill SUCLA2-deficeint prostate cancer cells.
Kanazawa University researchers reported that the SUCLA2 gene is frequently involved in the deletion of the tumor suppressor gene RB1 in advanced prostate cancer. RB1 deletion makes cells resistant to hormone therapy but SUCLA2 deletion induces a metabolic weakness. The study showed that thymoquinone selectively killed SUCLA2-deficient prostate cancer cells in vitro and in vivo. The findings highlight a vulnerability of advanced prostate cancer cells that can be targeted by drugs.
The compound thymoquinone (TQ) selectively kills prostate cancer cells at advanced stages, according to a new study published in Oncogene. Led by researchers at Kanazawa University, the study reports that prostate cancer cells with a deletion of the SUCLA2 gene can be therapeutically targeted. SUCLA2-deficient prostate cancers represent a significant fraction of those resistant to hormone therapy or metastatic, and a new therapeutic option for this disease would have immense benefits for patients.
Hormone therapy is often chosen for the treatment of metastatic prostate cancer but nearly half of patients develop resistance to the treatment in as little as 2 years. A mutation in RB1, a tumor suppressor gene that keeps cell growth under control, has been pegged as a particularly strong driver of treatment resistance and predicts poor outcome in patients.
“Mutations in tumor suppressor genes are enough to induce initiation and malignant progression of prostate cancer, but so far we haven’t been able to directly target these mutations with drugs to treat prostate cancer,” says the lead author Susumu Kohno. “We wanted to find a genetic aberration associated with that of a tumor suppressor gene which we could target therapeutically.”
In the genome, SUCLA2 neighbors RB1. An analysis of prostate cancer cells showed that cells with a RB1 deletion were also missing SUCLA2, pairing up the SUCLA2 deletion with the RB1 deletion present in advanced stage prostate cancer. Kohno and colleagues analyzed prostate cancer tissue and found that 11% of cases were missing both SUCLA2 and RB1.
The researchers screened compounds to identify drugs that would selectively kill cells with a SUCLA2 deletion. Out of around 2,000 compounds, TQ emerged as a hit compound. TQ already has known anti-cancer effects and was shown to be safe in a phase I clinical trial. Kohno and colleagues applied the TQ treatment to a mouse model of SUCLA2-deficient prostate cancer and TQ selectively suppressed tumor growth.
“These findings show that TQ treatment could be an effective therapy for treating prostate cancer cells that harbor SUCLA2 deficiency” says the senior author Chiaki Takahashi.
In a search of genetic databases from patients with prostate cancer, the researchers found that the frequency of SUCLA2 loss was almost perfectly aligned with RB1 loss at every disease stage—meaning the SUCLA2 deletion could identify people with prostate cancer needing advanced therapy.
Finding this drug-targetable vulnerability opens a crack in the barrier of treatment resistance for prostate cancer. More work needs to be done to improve efficacy of TQ and identify patients that would benefit from this type of treatment, but the compound provides a promising route for new treatment options for advanced prostate cancer.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Advanced prostate cancer
- Importance of radiotherapy to the primary in metastatic hormone sensitive prostate canceron April 8, 2021 at 10:19 am
In hindsight, there was likely early data to support the role of radiotherapy (RT) to the primary in metastatic prostate cancer. The 2011 NCIC/MRC PRO7 trial, asked the question of whether men with ...
- Dr. Ronney Abaza, A World Leader in Robotic Urologic and Cancer Surgery, Joins Central Ohio Urology Groupon April 6, 2021 at 4:38 am
Dr. Ronney Abaza, one of the world's leading robotic surgeons, joins Central Ohio Urology Group, one of the nation's leading urology practices.
- Differences in the Use of Fusion Biopsy Between Black and White Men Presenting with Suspicion of Prostate Cancer - Editorialon April 1, 2021 at 5:04 am
We have made major advances in our diagnosis and management of prostate cancer over the past 20 years. We now have new tools to diagnose localized (MRI) and advanced disease (next generation imaging).
- Racial Disparity in the Utilization of Multiparametric MRI–Ultrasound Fusion Biopsy for the Detection of Prostate Cancer - Full Text Articleon April 1, 2021 at 5:01 am
Advanced Prostate Cancer Alicia Morgans, MD, MPH CRPC with Bone Metastases Rana R. McKay, MD Imaging Center Phillip Koo, MD Localized Prostate Cancer Matthew R. Cooperberg, MD, MPH mCRPC Treatment ...
- Prostate Cancer | Tumoron March 27, 2021 at 5:00 pm
The Food and Drug Administration’s recent approval of the first oral hormone therapy, Orgovyx, for the treatment of advanced prostate cancer has positioned the drug to become a standard of care for ...
Go deeper with Google Headlines on:
Advanced prostate cancer
Go deeper with Bing News on:
- Rod Stewart addresses dangers of prostate cancer at clinic as he urges fans to get teston April 13, 2021 at 6:27 am
ROD STEWART shared a cheeky message on Instagram yesterday, while urging his fans to get checked for prostate cancer.
- Research could help diagnose prostate cancer severity more accuratelyon April 13, 2021 at 6:26 am
Scientists at the University of Alberta are part of a new research project to develop innovative precision diagnostics that could predict which men with prostate cancer are at risk of developing an ...
- Low health literacy may discourage men from selecting active surveillance for prostate canceron April 12, 2021 at 9:17 pm
Tumor gene profiling is a tool that can help patients with a cancer diagnosis make informed decisions about treatment.
- Research could lead to better treatment for aggressive prostate canceron April 12, 2021 at 5:43 pm
New research from CU Cancer Center member Scott Cramer, PhD, and his colleagues could help in the treatment of men with certain aggressive types of prostate cancer. Published this week in the journal ...
- Aberrant CREB1 activation in prostate cancer disrupts normal prostate luminal cell differentiationon April 12, 2021 at 10:18 am
Human prostate luminal cell differentiation requires NOTCH3 induction by p38-MAPK and MYC. J Cell Sci. 2017;130:1952–64. Henry GH, Malewska A, Joseph DB, Malladi VS, Lee J, Torrealba J, et al. A ...